Fosamax femur fracture risk outlined in new study
New research suggests that use of Fosamax may increase the risk of a rare type of low-energy femur fracture. Prolonged use of the osteoporosis drug may overly suppress bone metabolism, impacting the ability of the bone to repair microdamage to the femur.
The study is published in the May/June 2008 issue of the Journal of Orthopedic Trauma. Researchers performed a retrospective review of 70 low-energy femur fractures which resulted in emergency room treatment between January 2002 and March 2007. The fractures reviewed in the observational study involved injuries typically caused by the impacts of falls from a standing height or less.
Researchers identified a fracture pattern that was 98% specific to users of Fosamax, and the average duration of Fosamax use was longer among those who had the pattern than those who did not. Out of the 70 low-energy femur fractures reviewed, 25 involved users of Fosamax and 76% of the Fosamax femur fractures involved the distinct characteristics identified in the fracture pattern.
While Fosamax is prescribed to treat osteoporosis and reduce the risk of hip fractures and long bone fractures, the mechanism of action, which prevents bone turn-over, could make some users vulnerable to certain types of fractures. In addition to the low-energy femur fractures associated with Fosamax, users have also reported deterioration of the bone in the jaw, hip, knees and shoulders, which can cause permanently disabling injuries.
>>INFORMATION: Fosamax Side Effects
FOSAMAX LAWSUITS
The Fosamax lawyers at Saiontz & Kirk, P.A. currently represent individuals who have been diagnosed with osteonecrosis of the jaw (ONJ), or deterioration of the jaw bone. Potential cases are also being reviewed for individuals who have experienced necrosis of the hip, knee or shoulder as well as low-energy femur fractures. If you, a friend or family member have experienced an injury which could be caused by Fosamax side effects, request a free consultation and claim evaluation.
